Kosidło S, Rydzewska G, Gabryelewicz A
Gastroenterology Department, Medical Academy, Białystok, Poland.
Mater Med Pol. 1992 Oct-Dec;24(4):223-6.
The effect of new CCK receptor antagonist, lorglumid on taurocholate AEP in rats was studied. Lorglumid was applied intraperitoneally at a dose of 5.6 mg/kg BW immediately after taurocholate injection into choledochopancreatic duct. Activity of amylase, antithrombin III (AT III), alpha 1 protease inhibitor (alpha 1 PI), alpha 2 antiplasmin (alpha 2 AP) and alpha 2 M) in plasma, trypsin and chymotrypsin in pancreata were measured after 1, 3, 6 h of AEP. In AEP treated by lorglumid serum amylase activity and pancreatic wet weight was significantly reduced. The use of lorglumid prevented the increase of alpha 1 PI and alpha 2 AP compared to not treated animals. AT III and alpha 2 M in plasma and trypsin and chymotrypsin activity in pancreata did not change significantly in all groups. The mortality of the lorglumid treated rats was significantly lower in comparison with control group. It is concluded that lorglumid in taurocholate AEP moderates the changed plasma proteinase-antiproteinase balance. Our results indicate a protective effect of lorglumid in this model of acute experimental pancreatitis.
研究了新型胆囊收缩素（CCK）受体拮抗剂洛谷米德对大鼠牛磺胆酸盐诱导的急性胰腺炎（AEP）的影响。在将牛磺胆酸盐注入胆总管胰管后，立即以5.6 mg/kg体重的剂量腹腔注射洛谷米德。在AEP发生1、3、6小时后，测定血浆中淀粉酶、抗凝血酶III（AT III）、α1蛋白酶抑制剂（α1 PI）、α2抗纤溶酶（α2 AP）和α2巨球蛋白（α2 M）的活性，以及胰腺中胰蛋白酶和糜蛋白酶的活性。在洛谷米德治疗的AEP中，血清淀粉酶活性和胰腺湿重显著降低。与未治疗的动物相比，使用洛谷米德可防止α1 PI和α2 AP的增加。所有组中血浆中的AT III和α2 M以及胰腺中胰蛋白酶和糜蛋白酶的活性均无显著变化。与对照组相比，洛谷米德治疗的大鼠死亡率显著降低。结论是，在牛磺胆酸盐诱导的AEP中，洛谷米德可调节血浆蛋白酶-抗蛋白酶平衡的变化。我们的结果表明洛谷米德在这种急性实验性胰腺炎模型中具有保护作用。
